Reactive Astrocytes In Neurodegeneration is an important cell type in the neurobiology of neurodegenerative diseases. This page provides detailed information about its structure, function, and role in disease processes.
Reactive astrocytes are astrocytes that adopt a heightened state of activation in response to central nervous system (CNS) injury, infection, or neurodegeneration. First described in the late 19th century by Wilhelm His and subsequently characterized by Santiago Ramón y Cajal, these cells represent a fundamental response to neural pathology. In Alzheimer's disease (AD) and Parkinson's disease (PD), reactive astrocytes surround amyloid plaques and dopaminergic neuron loss sites, contributing to both protective and harmful outcomes 1.
The concept of reactive astrogliosis has evolved significantly since its initial description. Once viewed as a uniform response, it is now understood that reactive astrocytes exhibit diverse phenotypes depending on the pathological context, with distinct molecular signatures and functional outcomes 2.
Reactive astrocytes exist along a spectrum of activation states, broadly categorized into two main phenotypes designated A1 (neurotoxic) and A2 (neuroprotective). These phenotypes were first systematically defined by Liddelow and colleagues in 2017, who demonstrated that the A1 phenotype is induced by microglia-derived inflammatory cytokines 3.
The A1 phenotype represents a potentially damaging reactive state characterized by:
- Microglial induction: Triggered by microglia-derived cytokines including interleukin-1 alpha (IL-1α), tumor necrosis factor (TNF), and complement component 1q (C1q) 3
- NF-κB dependency: Nuclear factor kappa-light-chain-enhancer of activated B cells (NF-κB) signaling drives the A1 transcriptional program 4
- Complement upregulation: Increased expression of complement proteins including C3, C4, and Serping1
- Synaptic stripping: A1 astrocytes actively remove synapses through complement-mediated mechanisms, contributing to neuronal dysfunction 5
- Disease association: A1 astrocytes are prominently present in AD, PD, ALS, multiple sclerosis (MS), and Huntington's disease (HD)
The A2 phenotype represents a potentially beneficial reactive state characterized by:
- Ischemic induction: Primarily triggered by ischemic injury or hypoxia
- Neurotrophic factor production: Upregulated synthesis of brain-derived neurotrophic factor (BDNF), glial cell line-derived neurotrophic factor (GDNF), and nerve growth factor (NGF)
- Tissue repair genes: Enhanced expression of genes involved in wound healing and tissue remodeling
- Neuronal survival promotion: Support of neuronal viability through metabolic and trophic mechanisms
- Therapeutic target: Modulation of the A1-to-A2 transition represents a promising therapeutic strategy
The identification of phenotype-specific molecular markers enables characterization of astrocyte reactivity states in human disease.
- C3 (Complement Component 3): The most widely used A1 marker; elevated in AD, PD, and ALS brain tissue 6
- Serping1: Serpin family E member 1, involved in complement regulation
- Galectin-3 (LGALS3): Marker of reactive astrocytes in injury and disease
- GFAP upregulation: Glial fibrillary acidic protein increased but not specific to A1 state
- S100A10: Calcium-binding protein involved in plasminogen activation
- PTX3 (Pentraxin 3): Acute phase protein induced by inflammation
- Thrombospondins (THBS1/THBS2): Extracellular matrix proteins promoting synapse formation
- VEGF: Vascular endothelial growth factor with neuroprotective properties
Reactive astrocytes play complex and multifaceted roles in Alzheimer's disease pathogenesis, interacting with amyloid-beta (Aβ) plaques, tau pathology, and blood-brain barrier (BBB) dysfunction.
- Plaque containment: Reactive astrocytes form a protective barrier around amyloid plaques, limiting Aβ diffusion 7
- Aβ clearance: Astrocytes internalize and degrade Aβ through receptor-mediated uptake and lysosomal pathways 8
- Storage and release: Astrocytes can store Aβ and release it under pathological conditions
- Neuronal protection: A2 astrocytes support neuronal survival through trophic factor release
- Tau uptake: Astrocytes internalize pathological tau species from the extracellular space 9
- Propagation: Astrocytes may facilitate tau spreading between neurons through tunnel-like connections
- Neuron-to-astrocyte spread: Evidence suggests pathological tau can transfer from neurons to astrocytes
- Inflammatory amplification: Tau-containing astrocytes secrete pro-inflammatory cytokines, exacerbating neuroinflammation
- BBB maintenance: Healthy reactive astrocytes maintain BBB integrity through astrocyte-derived factors including angiopoietin-1 (ANGPT1) and GDNF 10
- Leakage in disease: In AD, reactive astrocytes contribute to BBB breakdown through matrix metalloproteinase (MMP) production
- Pericyte interaction: Astrocyte-endothelial-pericyte signaling regulates BBB function
- Transport regulation: Reactive astrocytes alter expression of transporters including P-glycoprotein and GLUT1
In Parkinson's disease, reactive astrocytes surround dopaminergic neurons in the substantia nigra pars compacta (SNc) and may both protect and contribute to disease progression.
- Neurotrophic support: Astrocytes secrete GDNF and BDNF, supporting dopaminergic neuron survival 11
- Glutamate clearance: Excitatory amino acid transporters (EAAT1/GLAST, EAAT2/GLT-1) regulate extracellular glutamate levels
- Antioxidant response: Astrocytes produce glutathione and other antioxidants protecting against oxidative stress
- Metabolic support: Astrocytes provide metabolic substrates including lactate to neurons
- Cytokine production: Reactive astrocytes produce TNF-α, IL-1β, IL-6, and other pro-inflammatory mediators 12
- Chemokine secretion: CCL2, CXCL1, and other chemokines attract immune cells to the brain
- Gliosis: Proliferation and hypertrophy of astrocytes forming glial scars
- Disease progression: Chronic astrocyte reactivity may contribute to dopaminergic neuron loss
Understanding astrocyte reactivity provides therapeutic opportunities for neurodegenerative disease modification.
- A1 to A2 conversion: Identification of compounds promoting the A2 phenotype
- NF-κB inhibition: Targeting the NF-κB pathway to reduce A1 polarization 13
- Cytokine blockade: Blocking microglial cytokines (IL-1α, TNF, C1q) preventing A1 induction
- TREM2 effects: TREM2 signaling in microglia influences astrocyte reactivity 14
- GDNF delivery: Glial cell line-derived neurotrophic factor family ligands for dopaminergic protection 15
- BDNF support: Brain-derived neurotrophic factor for synaptic plasticity
- NGF signaling: Nerve growth factor for cholinergic neuron survival
- Repair promotion: Enhancing astrocyte-mediated tissue repair mechanisms
The study of Reactive Astrocytes In Neurodegeneration has evolved significantly over the past decades. Research in this area has revealed important insights into the underlying mechanisms of neurodegeneration and continues to drive therapeutic development.
Historical context and key discoveries in this field have shaped our current understanding and will continue to guide future research directions.
- Liddelow & Barres (2019). Neurotoxic vs. protective reactive astrocytes. Trends in Neurosciences
- Sofroniew (2015). Astrogliosis. Cold Spring Harbor Perspectives in Biology
- Liddelow et al. (2017). Neurotoxic reactive astrocytes are induced by activated microglia. Nature
- Barres (2008). The mystery and magic of glia. Cell
- Chung et al. (2018). Complement and microglia mediate synapse elimination. Neuron
- Yun et al. (2018). A1 astrocytes and neuronal loss in Alzheimer's disease. Nature
- Nagele et al. (2003). Astrocytes accumulate Aβ in Alzheimer's disease brains. Neurobiology of Aging
- Wyss-Coray et al. (2003). Adult mouse astrocytes. Journal of Neurochemistry
- Ferrer (2018). Tau uptake by astrocytes. Neurobiology of Aging
- Muoio et al. (2018). Astrocyte-derived factors and blood-brain barrier. Neuropharmacology
- Saavedra et al. (2017). Astrocyte GDNF in Parkinson's disease. Journal of Molecular Neuroscience
- Song et al. (2021). Astrocyte dysfunction in Parkinson's disease. Journal of Parkinson's Disease
- Green et al. (2021). NF-κB inhibition reduces A1 astrocytes. Nature Medicine
- Vanderburg et al. (2020). TREM2 and astrocyte reactivity in AD. Neuron
- Kordower et al. (2018). GDNF delivery in Parkinson's disease. Molecular Therapy